Trexquant Investment LP Invests $1.31 Million in Alphatec Holdings, Inc. $ATEC

Key Points

• Trexquant Investment LP acquired 129,496 shares of Alphatec Holdings, Inc. in the first quarter, valued at approximately $1.3 million, representing a 0.09% ownership stake.
• CEO Patrick Miles sold 300,000 shares for $4.7 million, decreasing his ownership by 5.12%, while insiders overall sold 510,247 shares worth $7.6 million in recent months.
• Analysts have mixed views on Alphatec, with target prices ranging from $18 to $22, while the stock has recently been rated as a "buy" by several firms but downgraded to "hold" by others.

Trexquant Investment LP acquired a new stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 129,496 shares of the medical technology company's stock, valued at approximately $1,313,000. Trexquant Investment LP owned 0.09% of Alphatec as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of ATEC. Nuveen LLC acquired a new position in Alphatec during the first quarter worth approximately $135,874,000. Royal Bank of Canada increased its position in Alphatec by 171.2% during the fourth quarter. Royal Bank of Canada now owns 3,185,283 shares of the medical technology company's stock worth $29,240,000 after purchasing an additional 2,010,806 shares during the last quarter. MetLife Investment Management LLC increased its position in Alphatec by 1,818.5% during the first quarter. MetLife Investment Management LLC now owns 1,213,943 shares of the medical technology company's stock worth $12,309,000 after purchasing an additional 1,150,669 shares during the last quarter. Nuveen Asset Management LLC increased its position in shares of Alphatec by 78.4% in the fourth quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company's stock worth $23,730,000 after acquiring an additional 1,136,330 shares in the last quarter. Finally, Motley Fool Wealth Management LLC acquired a new stake in shares of Alphatec in the first quarter worth $9,070,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Insider Transactions at Alphatec

In related news, COO Scott Lish sold 6,323 shares of Alphatec stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $16.01, for a total value of $101,231.23. Following the sale, the chief operating officer directly owned 658,707 shares in the company, valued at $10,545,899.07. This trade represents a 0.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mortimer Berkowitz III sold 62,500 shares of Alphatec stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $15.97, for a total transaction of $998,125.00. Following the completion of the sale, the director owned 618,050 shares in the company, valued at approximately $9,870,258.50. This represents a 9.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 568,784 shares of company stock worth $8,577,660 over the last 90 days. Corporate insiders own 20.90% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Barclays reissued an "overweight" rating and issued a $22.00 price objective (up previously from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $20.00 price target on shares of Alphatec in a report on Friday, August 1st. Wall Street Zen raised shares of Alphatec from a "hold" rating to a "buy" rating in a report on Sunday. Finally, Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 price target for the company in a report on Monday, June 16th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $18.50.

Alphatec Stock Performance

Shares of Alphatec stock traded up $0.28 during trading hours on Thursday, reaching $15.63. The company's stock had a trading volume of 2,416,442 shares, compared to its average volume of 1,943,302. The stock has a market cap of $2.31 billion, a P/E ratio of -13.83 and a beta of 1.02. The company's 50 day simple moving average is $13.76 and its 200 day simple moving average is $12.05. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $16.70. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.08. The firm had revenue of $185.54 million for the quarter, compared to the consensus estimate of $178.85 million. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. Alphatec's quarterly revenue was up 27.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.29) EPS. Alphatec has set its FY 2025 guidance at EPS. As a group, analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.